{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:45:41Z","timestamp":1791927941726,"version":"4.3.4"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,31]]},"DOI":"10.7759\/cureus.81512","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T15:42:10Z","timestamp":1743435730000},"source":"Crossref","is-referenced-by-count":6,"title":["Obesity-Related Phenotype of Heart Failure With Preserved Ejection Fraction: A Comprehensive Review"],"prefix":"10.7759","author":[{"given":"Taha","family":"El Hadj Othmane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"El Hadj Othmane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Nizar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.320257","article-title":"Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models","volume":"130","author":"Roh J","year":"2022","unstructured":"Roh J, Hill JA, Singh A, Valero-Mu\u00f1oz M, Sam F. Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models. Circ Res. 2022, 130:1906-25. 10.1161\/CIRCRESAHA.122.320257","journal-title":"Circ Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010242","article-title":"Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding","volume":"9","author":"Simmonds SJ","year":"2020","unstructured":"Simmonds SJ, Cuijpers I, Heymans S, Jones EA. Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding. Cells. 2020, 9:242. 10.3390\/cells9010242","journal-title":"Cells"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata M","year":"2017","unstructured":"Obokata M, Reddy YN, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017, 136:6-19. 10.1161\/CIRCULATIONAHA.116.026807","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.23736\/S0026-4806.17.05022-4","article-title":"Obesity and cardiovascular diseases","volume":"108","author":"Kachur S","year":"2017","unstructured":"Kachur S, Lavie CJ, de Schutter A, Milani RV, Ventura HO. Obesity and cardiovascular diseases. Minerva Med. 2017, 108:212-28. 10.23736\/S0026-4806.17.05022-4","journal-title":"Minerva Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart\u00a0failure with preserved ejection\u00a0fraction: JACC scientific statement","volume":"81","author":"Borlaug BA","year":"2023","unstructured":"Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart\u00a0failure with preserved ejection\u00a0fraction: JACC scientific statement. J Am Coll Cardiol. 2023, 81:1810-34. 10.1016\/j.jacc.2023.01.049","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12092112","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists in the management of obesity-related heart failure with preserved ejection fraction: benefits beyond what scales can measure?","volume":"12","author":"Karakasis P","year":"2024","unstructured":"Karakasis P, Fragakis N, Patoulias D, et al.. The emerging role of glucagon-like peptide-1 receptor agonists in the management of obesity-related heart failure with preserved ejection fraction: benefits beyond what scales can measure?. Biomedicines. 2024, 12:2112. 10.3390\/biomedicines12092112","journal-title":"Biomedicines"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2013.01.006","article-title":"Impact of obesity and the obesity paradox on prevalence and prognosis in heart\u00a0failure","volume":"1","author":"Lavie CJ","year":"2013","unstructured":"Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart\u00a0failure. JACC Heart Fail. 2013, 1:93-102. 10.1016\/j.jchf.2013.01.006","journal-title":"JACC Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2022.271","article-title":"Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges","volume":"38","author":"Jung MH","year":"2023","unstructured":"Jung MH, Shin MS. Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges. Korean J Intern Med. 2023, 38:157-66. 10.3904\/kjim.2022.271","journal-title":"Korean J Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.03.026","article-title":"The hemodynamic obesity paradox: decoupling of hemodynamics and congestive symptoms in patients with heart failure and obesity","volume":"29","author":"Swat S","year":"2023","unstructured":"Swat S, Tannu M, Grinstein J, Upadhya B. The hemodynamic obesity paradox: decoupling of hemodynamics and congestive symptoms in patients with heart failure and obesity. J Card Fail. 2023, 29:1257-60. 10.1016\/j.cardfail.2023.03.026","journal-title":"J Card Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000868","article-title":"Interactions of hypertension, obesity, left ventricular hypertrophy, and heart failure","volume":"36","author":"daSilva-deAbreu A","year":"2021","unstructured":"daSilva-deAbreu A, Alhafez BA, Lavie CJ, Milani RV, Ventura HO. Interactions of hypertension, obesity, left ventricular hypertrophy, and heart failure. Curr Opin Cardiol. 2021, 36:453-60. 10.1097\/HCO.0000000000000868","journal-title":"Curr Opin Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Pich\u00e9 ME","year":"2020","unstructured":"Pich\u00e9 ME, Tchernof A, Despr\u00e9s JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020, 126:1477-500. 10.1161\/CIRCRESAHA.120.316101","journal-title":"Circ Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-023-01510-6","article-title":"Sleep apnea, obesity, and diabetes - an intertwined trio","volume":"23","author":"Kurnool S","year":"2023","unstructured":"Kurnool S, McCowen KC, Bernstein NA, Malhotra A. Sleep apnea, obesity, and diabetes - an intertwined trio. Curr Diab Rep. 2023, 23:165-71. 10.1007\/s11892-023-01510-6","journal-title":"Curr Diab Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman DW","year":"2016","unstructured":"Kitzman DW, Brubaker P, Morgan T, et al.. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2016, 315:36-46. 10.1001\/jama.2015.17346","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.08.069","article-title":"Long-term caloric restriction ameliorates the decline in diastolic function in humans","volume":"47","author":"Meyer TE","year":"2006","unstructured":"Meyer TE, Kov\u00e1cs SJ, Ehsani AA, Klein S, Holloszy JO, Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol. 2006, 47:398-402. 10.1016\/j.jacc.2005.08.069","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1381\/096089206777346673","article-title":"Estimating blood volume in obese and morbidly obese patients","volume":"16","author":"Lemmens HJ","year":"2006","unstructured":"Lemmens HJ, Bernstein DP, Brodsky JB. Estimating blood volume in obese and morbidly obese patients. Obes Surg. 2006, 16:773-6. 10.1381\/096089206777346673","journal-title":"Obes Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-199409000-00012","article-title":"Obesity and hypertension","volume":"3","author":"Schmieder RE","year":"1994","unstructured":"Schmieder RE, Rockstroh JK. Obesity and hypertension. Curr Opin Nephrol Hypertens. 1994, 3:546-9. 10.1097\/00041552-199409000-00012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.07.034","article-title":"The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA\/KORA (monitoring of trends and determinations in cardiovascular disease\/cooperative research in the region of Augsburg) study","volume":"54","author":"Stritzke J","year":"2009","unstructured":"Stritzke J, Markus MR, Duderstadt S, et al.. The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA\/KORA (monitoring of trends and determinations in cardiovascular disease\/cooperative research in the region of Augsburg) study. J Am Coll Cardiol. 2009, 54:1982-9. 10.1016\/j.jacc.2009.07.034","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2021.03.066","article-title":"Left ventricular diastolic dysfunction among youth with obesity and history of elevated blood pressure","volume":"235","author":"Abdul-Raheem JN","year":"2021","unstructured":"Abdul-Raheem JN, Binka E, Roem J, Turer CB, Urbina EM, Brady TM. Left ventricular diastolic dysfunction among youth with obesity and history of elevated blood pressure. J Pediatr. 2021, 235:130-7. 10.1016\/j.jpeds.2021.03.066","journal-title":"J Pediatr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2018.01.006","article-title":"Effects of weight changes in the autonomic nervous system: a\u00a0systematic review and meta-analysis","volume":"38","author":"Costa J","year":"2019","unstructured":"Costa J, Moreira A, Moreira P, Delgado L, Silva D. Effects of weight changes in the autonomic nervous system: a\u00a0systematic review and meta-analysis. Clin Nutr. 2019, 38:110-26. 10.1016\/j.clnu.2018.01.006","journal-title":"Clin Nutr"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2018.07.012","article-title":"Obesity and cardiac remodeling in adults: mechanisms and clinical implications","volume":"61","author":"Alpert MA","year":"2018","unstructured":"Alpert MA, Karthikeyan K, Abdullah O, Ghadban R. Obesity and cardiac remodeling in adults: mechanisms and clinical implications. Prog Cardiovasc Dis. 2018, 61:114-23. 10.1016\/j.pcad.2018.07.012","journal-title":"Prog Cardiovasc Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084195","article-title":"Remodeling and fibrosis of the cardiac muscle in the course of obesity-pathogenesis and involvement of the extracellular matrix","volume":"23","author":"Kruszewska J","year":"2022","unstructured":"Kruszewska J, Cudnoch-Jedrzejewska A, Czarzasta K. Remodeling and fibrosis of the cardiac muscle in the course of obesity-pathogenesis and involvement of the extracellular matrix. Int J Mol Sci. 2022, 23:4196. 10.3390\/ijms23084195","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00017.2007","article-title":"Cardiac remodeling in obesity","volume":"88","author":"Abel ED","year":"2008","unstructured":"Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008, 88:389-419. 10.1152\/physrev.00017.2007","journal-title":"Physiol Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.771022","article-title":"Arterial and cardiac remodeling associated with extra weight gain in an isolated abdominal obesity cohort","volume":"8","author":"Mandry D","year":"2021","unstructured":"Mandry D, Girerd N, Lamiral Z, et al.. Arterial and cardiac remodeling associated with extra weight gain in an isolated abdominal obesity cohort. Front Cardiovasc Med. 2021, 8:771022. 10.3389\/fcvm.2021.771022","journal-title":"Front Cardiovasc Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12997","article-title":"Adipokine dysregulation and adipose tissue inflammation in human obesity","volume":"48","author":"Unamuno X","year":"2018","unstructured":"Unamuno X, G\u00f3mez-Ambrosi J, Rodr\u00edguez A, Becerril S, Fr\u00fchbeck G, Catal\u00e1n V. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur J Clin Invest. 2018, 48:e12997. 10.1111\/eci.12997","journal-title":"Eur J Clin Invest"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02672-y","article-title":"Obese visceral fat tissue inflammation: from protective to detrimental?","volume":"20","author":"Kolb H","year":"2022","unstructured":"Kolb H. Obese visceral fat tissue inflammation: from protective to detrimental?. BMC Med. 2022, 20:494. 10.1186\/s12916-022-02672-y","journal-title":"BMC Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus WJ","year":"2013","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013, 62:263-71. 10.1016\/j.jacc.2013.02.092","journal-title":"J Am Coll Cardiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092534","article-title":"Endothelial dysfunction in heart failure: what is its role?","volume":"13","author":"Drera A","year":"2024","unstructured":"Drera A, Rodella L, Brangi E, Riccardi M, Vizzardi E. Endothelial dysfunction in heart failure: what is its role?. J Clin Med. 2024, 13:2534. 10.3390\/jcm13092534","journal-title":"J Clin Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-013-1349-6","article-title":"The pathogenesis of cardiac fibrosis","volume":"71","author":"Kong P","year":"2014","unstructured":"Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014, 71:549-74. 10.1007\/s00018-013-1349-6","journal-title":"Cell Mol Life Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2005.12.009","article-title":"Myocardial proteases and matrix remodeling in inflammatory heart disease","volume":"69","author":"Rutschow S","year":"2006","unstructured":"Rutschow S, Li J, Schultheiss HP, Pauschinger M. Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res. 2006, 69:646-56. 10.1016\/j.cardiores.2005.12.009","journal-title":"Cardiovasc Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2014.05.001","article-title":"Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities","volume":"164","author":"Cavalera M","year":"2014","unstructured":"Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res. 2014, 164:323-35. 10.1016\/j.trsl.2014.05.001","journal-title":"Transl Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1113\/JP276747","article-title":"Cardiomyopathy in obesity, insulin resistance and diabetes","volume":"598","author":"Nakamura M","year":"2020","unstructured":"Nakamura M, Sadoshima J. Cardiomyopathy in obesity, insulin resistance and diabetes. J Physiol. 2020, 598:2977-93. 10.1113\/JP276747","journal-title":"J Physiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.107.165472","article-title":"Role of mitochondrial dysfunction in insulin resistance","volume":"102","author":"Kim JA","year":"2008","unstructured":"Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res. 2008, 102:401-14. 10.1161\/CIRCRESAHA.107.165472","journal-title":"Circ Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.04.001","article-title":"Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024","volume":"18","author":"Bays HE","year":"2024","unstructured":"Bays HE, Kirkpatrick CF, Maki KC, et al.. Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. J Clin Lipidol. 2024, 18:e320-50. 10.1016\/j.jacl.2024.04.001","journal-title":"J Clin Lipidol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2016.02.016","article-title":"Lipid metabolism and signaling in cardiac lipotoxicity","volume":"1861","author":"D'Souza K","year":"2016","unstructured":"D'Souza K, Nzirorera C, Kienesberger PC. Lipid metabolism and signaling in cardiac lipotoxicity. Biochim Biophys Acta. 2016, 1861:1513-24. 10.1016\/j.bbalip.2016.02.016","journal-title":"Biochim Biophys Acta"},{"key":"ref35","article-title":"Obesity: definition, comorbidities, causes, and burden","volume":"22","author":"Apovian CM","year":"2016","unstructured":"Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016, 22:s176-85.","journal-title":"Am J Manag Care"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley TM","year":"2021","unstructured":"Powell-Wiley TM, Poirier P, Burke LE, et al.. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021, 143:e984-e1010. 10.1161\/CIR.0000000000000973","journal-title":"Circulation"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug BA","year":"2014","unstructured":"Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014, 11:507-15. 10.1038\/nrcardio.2014.83","journal-title":"Nat Rev Cardiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.05.013","article-title":"Obesity and hypertension","volume":"122","author":"Seravalle G","year":"2017","unstructured":"Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017, 122:1-7. 10.1016\/j.phrs.2017.05.013","journal-title":"Pharmacol Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-317326","article-title":"Obstructive sleep apnoea, intermittent hypoxia and heart failure with a preserved ejection fraction","volume":"107","author":"Sanderson JE","year":"2021","unstructured":"Sanderson JE, Fang F, Lu M, Ma CY, Wei YX. Obstructive sleep apnoea, intermittent hypoxia and heart failure with a preserved ejection fraction. Heart. 2021, 107:190-4. 10.1136\/heartjnl-2020-317326","journal-title":"Heart"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1007\/164_2021_558","article-title":"Obesity and obstructive sleep apnea","volume":"274","author":"Bonsignore MR","year":"2022","unstructured":"Bonsignore MR. Obesity and obstructive sleep apnea. Handb Exp Pharmacol. 2022, 274:181-201. 10.1007\/164_2021_558","journal-title":"Handb Exp Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.071233","article-title":"Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine","volume":"92","author":"Weber M","year":"2006","unstructured":"Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006, 92:843-9. 10.1136\/hrt.2005.071233","journal-title":"Heart"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.08.007","article-title":"Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure","volume":"176","author":"Madamanchi C","year":"2014","unstructured":"Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014, 176:611-7. 10.1016\/j.ijcard.2014.08.007","journal-title":"Int J Cardiol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12235","article-title":"Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction","volume":"5","author":"Buckley LF","year":"2018","unstructured":"Buckley LF, Canada JM, Del Buono MG, et al.. Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Fail. 2018, 5:372-8. 10.1002\/ehf2.12235","journal-title":"ESC Heart Fail"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2019.09.010","article-title":"Impact of obesity on volume status in patients with ambulatory chronic heart failure","volume":"26","author":"Miller WL","year":"2020","unstructured":"Miller WL, Borlaug BA. Impact of obesity on volume status in patients with ambulatory chronic heart failure. J Card Fail. 2020, 26:112-7. 10.1016\/j.cardfail.2019.09.010","journal-title":"J Card Fail"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.017298","article-title":"N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"133","author":"Ndumele CE","year":"2016","unstructured":"Ndumele CE, Matsushita K, Sang Y, et al.. N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2016, 133:631-8. 10.1161\/CIRCULATIONAHA.115.017298","journal-title":"Circulation"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2618","article-title":"Clinical effect of obesity on N-terminal pro-B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure","volume":"24","author":"Kozhuharov N","year":"2022","unstructured":"Kozhuharov N, Martin J, Wussler D, et al.. Clinical effect of obesity on N-terminal pro-B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure. Eur J Heart Fail. 2022, 24:1545-54. 10.1002\/ejhf.2618","journal-title":"Eur J Heart Fail"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023238","article-title":"Obesity, galectin-3, and incident heart failure: the ARIC Study","volume":"11","author":"Florido R","year":"2022","unstructured":"Florido R, Kwak L, Echouffo-Tcheugui JB, et al.. Obesity, galectin-3, and incident heart failure: the ARIC Study. J Am Heart Assoc. 2022, 11:e023238. 10.1161\/JAHA.121.023238","journal-title":"J Am Heart Assoc"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2022.27","article-title":"Imaging in heart failure with preserved ejection fraction: a multimodality imaging point of view","volume":"9","author":"\u00dcnl\u00fc S","year":"2023","unstructured":"\u00dcnl\u00fc S, \u00d6zden \u00d6, \u00c7elik A. Imaging in heart failure with preserved ejection fraction: a multimodality imaging point of view. Card Fail Rev. 2023, 9:e04. 10.15420\/cfr.2022.27","journal-title":"Card Fail Rev"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2003.029413","article-title":"Assessment of diastolic function: what the general cardiologist needs to know","volume":"91","author":"Mottram PM","year":"2005","unstructured":"Mottram PM, Marwick TH. Assessment of diastolic function: what the general cardiologist needs to know. Heart. 2005, 91:681-95. 10.1136\/hrt.2003.029413","journal-title":"Heart"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2020.03.009","article-title":"Echocardiography in the era of obesity","volume":"33","author":"El Hajj MC","year":"2020","unstructured":"El Hajj MC, Litwin SE. Echocardiography in the era of obesity. J Am Soc Echocardiogr. 2020, 33:779-87. 10.1016\/j.echo.2020.03.009","journal-title":"J Am Soc Echocardiogr"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79729-6","article-title":"Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction","volume":"11","author":"Garg P","year":"2021","unstructured":"Garg P, Assadi H, Jones R, et al.. Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction. Sci Rep. 2021, 11:617. 10.1038\/s41598-020-79729-6","journal-title":"Sci Rep"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3390\/tomography7040075","article-title":"Diastolic cardiac function by MRI-imaging capabilities and clinical applications","volume":"7","author":"Ibrahim EH","year":"2021","unstructured":"Ibrahim EH, Dennison J, Frank L, Stojanovska J. Diastolic cardiac function by MRI-imaging capabilities and clinical applications. Tomography. 2021, 7:893-914. 10.3390\/tomography7040075","journal-title":"Tomography"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.022930","article-title":"Pragmatic weight management program for patients with obesity and heart failure with preserved ejection fraction","volume":"10","author":"El Hajj EC","year":"2021","unstructured":"El Hajj EC, El Hajj MC, Sykes B, et al.. Pragmatic weight management program for patients with obesity and heart failure with preserved ejection fraction. J Am Heart Assoc. 2021, 10:e022930. 10.1161\/JAHA.121.022930","journal-title":"J Am Heart Assoc"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.681726","article-title":"Weight change and mortality risk in heart failure with preserved ejection fraction","volume":"8","author":"Huang P","year":"2021","unstructured":"Huang P, Guo Z, Liang W, et al.. Weight change and mortality risk in heart failure with preserved ejection fraction. Front Cardiovasc Med. 2021, 8:681726. 10.3389\/fcvm.2021.681726","journal-title":"Front Cardiovasc Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug BA","year":"2023","unstructured":"Borlaug BA, Jensen MD, Kitzman DW, Lam CS, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023, 118:3434-50. 10.1093\/cvr\/cvac120","journal-title":"Cardiovasc Res"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306187","article-title":"CPAP, weight loss, or both for obstructive sleep apnea","volume":"370","author":"Chirinos JA","year":"2014","unstructured":"Chirinos JA, Gurubhagavatula I, Teff K, et al.. CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med. 2014, 370:2265-75. 10.1056\/NEJMoa1306187","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010161","article-title":"A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction","volume":"16","author":"Brubaker PH","year":"2023","unstructured":"Brubaker PH, Nicklas BJ, Houston DK, et al.. A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction. Circ Heart Fail. 2023, 16:e010161. 10.1161\/CIRCHEARTFAILURE.122.010161","journal-title":"Circ Heart Fail"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v13.i9.514","article-title":"Effects of exercise training on diastolic and systolic dysfunction in patients with chronic heart failure","volume":"13","author":"Chaveles I","year":"2021","unstructured":"Chaveles I, Papazachou O, Shamari MA, et al.. Effects of exercise training on diastolic and systolic dysfunction in patients with chronic heart failure. World J Cardiol. 2021, 13:514-25. 10.4330\/wjc.v13.i9.514","journal-title":"World J Cardiol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4865756","article-title":"Targeting endothelial function to treat heart failure with preserved ejection fraction: the promise of exercise training","volume":"2017","author":"Gevaert AB","year":"2017","unstructured":"Gevaert AB, Lemmens K, Vrints CJ, Van Craenenbroeck EM. Targeting endothelial function to treat heart failure with preserved ejection fraction: the promise of exercise training. Oxid Med Cell Longev. 2017, 2017:4865756. 10.1155\/2017\/4865756","journal-title":"Oxid Med Cell Longev"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1194693","article-title":"Personalized remotely guided preventive exercise therapy for a healthy heart (PRIORITY): protocol for an assessor-blinded, multicenter randomized controlled trial","volume":"10","author":"De Wilde C","year":"2023","unstructured":"De Wilde C, Bekhuis Y, Kuznetsova T, et al.. Personalized remotely guided preventive exercise therapy for a healthy heart (PRIORITY): protocol for an assessor-blinded, multicenter randomized controlled trial. Front Cardiovasc Med. 2023, 10:1194693. 10.3389\/fcvm.2023.1194693","journal-title":"Front Cardiovasc Med"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101465","article-title":"Dietary interventions in heart\u00a0failure with preserved ejection fraction: a scoping review","volume":"4","author":"Billingsley HE","year":"2025","unstructured":"Billingsley HE, Carbone S, Driggin E, Kitzman DW, Hummel SL. Dietary interventions in heart\u00a0failure with preserved ejection fraction: a scoping review. JACC Adv. 2025, 4:101465. 10.1016\/j.jacadv.2024.101465","journal-title":"JACC Adv"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif ME","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al.. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021, 27:1954-60. 10.1038\/s41591-021-01536-x","journal-title":"Nat Med"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1093\/postmj\/qgad022","article-title":"The use of sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: new guidelines hot off the press and directly into guidelines!","volume":"99","author":"Clark KA","year":"2023","unstructured":"Clark KA. The use of sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: new guidelines hot off the press and directly into guidelines!. Postgrad Med J. 2023, 99:1052-7. 10.1093\/postmj\/qgad022","journal-title":"Postgrad Med J"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk GD","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020, 5:632-44. 10.1016\/j.jacbts.2020.02.004","journal-title":"JACC Basic Transl Sci"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann F","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG, et al.. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013, 309:781-91. 10.1001\/jama.2013.905","journal-title":"JAMA"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-018-9758-0","article-title":"Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Kapelios CJ","year":"2019","unstructured":"Kapelios CJ, Murrow JR, N\u00fchrenberg TG, Montoro Lopez MN. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev. 2019, 24:367-77. 10.1007\/s10741-018-9758-0","journal-title":"Heart Fail Rev"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt B","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, et al.. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014, 370:1383-92. 10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.594986","article-title":"Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox","volume":"114","author":"Strauss MH","year":"2006","unstructured":"Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006, 114:838-54. 10.1161\/CIRCULATIONAHA.105.594986","journal-title":"Circulation"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"Pfeffer MA","year":"2019","unstructured":"Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019, 124:1598-617. 10.1161\/CIRCRESAHA.119.313572","journal-title":"Circ Res"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2024.2363395","article-title":"Targeting obesity for therapeutic intervention in heart failure patients","volume":"22","author":"Sato R","year":"2024","unstructured":"Sato R, von Haehling S. Targeting obesity for therapeutic intervention in heart failure patients. Expert Rev Cardiovasc Ther. 2024, 22:217-30. 10.1080\/14779072.2024.2363395","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-024-10439-1","article-title":"Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities [in press]","author":"Vacca A","year":"2024","unstructured":"Vacca A, Wang R, Nambiar N, et al.. Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities [in press]. Heart Fail Rev. 2024, 10.1007\/s10741-024-10439-1","journal-title":"Heart Fail Rev"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2022-321097","article-title":"Management of patients with heart failure and preserved ejection fraction","volume":"109","author":"Jasinska-Piadlo A","year":"2023","unstructured":"Jasinska-Piadlo A, Campbell P. Management of patients with heart failure and preserved ejection fraction. Heart. 2023, 109:874-83. 10.1136\/heartjnl-2022-321097","journal-title":"Heart"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12196139","article-title":"Association between obstructive sleep apnea and heart failure in adults-a systematic review","volume":"12","author":"Polecka A","year":"2023","unstructured":"Polecka A, Olszewska N, Danielski \u0141, Olszewska E. Association between obstructive sleep apnea and heart failure in adults-a systematic review. J Clin Med. 2023, 12:6139. 10.3390\/jcm12196139","journal-title":"J Clin Med"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028733","article-title":"Positive airway pressure therapy adherence and health care resource use in patients with obstructive sleep apnea and heart failure with preserved ejection fraction","volume":"12","author":"Cistulli PA","year":"2023","unstructured":"Cistulli PA, Malhotra A, Cole KV, et al.. Positive airway pressure therapy adherence and health care resource use in patients with obstructive sleep apnea and heart failure with preserved ejection fraction. J Am Heart Assoc. 2023, 12:e028733. 10.1161\/JAHA.122.028733","journal-title":"J Am Heart Assoc"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-023-10346-x","article-title":"Assessment and management of heart failure in patients with chronic kidney disease","volume":"29","author":"Guaricci AI","year":"2024","unstructured":"Guaricci AI, Sturd\u00e0 F, Russo R, et al.. Assessment and management of heart failure in patients with chronic kidney disease. Heart Fail Rev. 2024, 29:379-94. 10.1007\/s10741-023-10346-x","journal-title":"Heart Fail Rev"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01108","article-title":"Chronic kidney disease as a risk factor for heart failure with preserved ejection fraction: a focus on microcirculatory factors and therapeutic targets","volume":"10","author":"van de Wouw J","year":"2019","unstructured":"van de Wouw J, Broekhuizen M, Sorop O, et al.. Chronic kidney disease as a risk factor for heart failure with preserved ejection fraction: a focus on microcirculatory factors and therapeutic targets. Front Physiol. 2019, 10:1108. 10.3389\/fphys.2019.01108","journal-title":"Front Physiol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.947147","article-title":"Inflamed adipose tissue: a culprit underlying obesity and heart failure with preserved ejection fraction","volume":"13","author":"Li C","year":"2022","unstructured":"Li C, Qin D, Hu J, Yang Y, Hu D, Yu B. Inflamed adipose tissue: a culprit underlying obesity and heart failure with preserved ejection fraction. Front Immunol. 2022, 13:947147. 10.3389\/fimmu.2022.947147","journal-title":"Front Immunol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac133","article-title":"Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions","volume":"118","author":"Pugliese NR","year":"2023","unstructured":"Pugliese NR, Pellicori P, Filidei F, et al.. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovasc Res. 2023, 118:3536-55. 10.1093\/cvr\/cvac133","journal-title":"Cardiovasc Res"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-07071-0","article-title":"Inflammatory cytokines and chemokines as therapeutic targets in heart failure","volume":"34","author":"Hanna A","year":"2020","unstructured":"Hanna A, Frangogiannis NG. Inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc Drugs Ther. 2020, 34:849-63. 10.1007\/s10557-020-07071-0","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010618","article-title":"Obesity-related biomarkers are associated with exercise intolerance and HFpEF","volume":"16","author":"Ramirez MF","year":"2023","unstructured":"Ramirez MF, Lau ES, Parekh JK, et al.. Obesity-related biomarkers are associated with exercise intolerance and HFpEF. Circ Heart Fail. 2023, 16:e010618. 10.1161\/CIRCHEARTFAILURE.123.010618","journal-title":"Circ Heart Fail"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited","volume":"128","author":"Paulus WJ","year":"2021","unstructured":"Paulus WJ, Zile MR. From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited. Circ Res. 2021, 128:1451-67. 10.1161\/CIRCRESAHA.121.318159","journal-title":"Circ Res"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00034","article-title":"Therapeutic targets for the treatment of cardiac fibrosis and cancer: focusing on TGF-\u03b2 signaling","volume":"7","author":"Parichatikanond W","year":"2020","unstructured":"Parichatikanond W, Luangmonkong T, Mangmool S, Kurose H. Therapeutic targets for the treatment of cardiac fibrosis and cancer: focusing on TGF-\u03b2 signaling. Front Cardiovasc Med. 2020, 7:34. 10.3389\/fcvm.2020.00034","journal-title":"Front Cardiovasc Med"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910865","article-title":"Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?","volume":"12","author":"Sweeney M","year":"2020","unstructured":"Sweeney M, Corden B, Cook SA. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?. EMBO Mol Med. 2020, 12:e10865. 10.15252\/emmm.201910865","journal-title":"EMBO Mol Med"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15062","article-title":"Heart failure and diabetes: clinical significance and epidemiology of this two-way association","volume":"25 Suppl 3","author":"Jerkins T","year":"2023","unstructured":"Jerkins T, McGill JB, Bell DS. Heart failure and diabetes: clinical significance and epidemiology of this two-way association. Diabetes Obes Metab. 2023, 25 Suppl 3:3-14. 10.1111\/dom.15062","journal-title":"Diabetes Obes Metab"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-84. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042496","article-title":"HFpEF-time to explore the role of genetic heterogeneity in phenotypic variability: new mechanistic insights offer promise for personalized therapies","volume":"140","author":"Porrello ER","year":"2019","unstructured":"Porrello ER, Delbridge LM. HFpEF-time to explore the role of genetic heterogeneity in phenotypic variability: new mechanistic insights offer promise for personalized therapies. Circulation. 2019, 140:1607-9. 10.1161\/CIRCULATIONAHA.119.042496","journal-title":"Circulation"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35323-0","article-title":"Genetic architecture of heart failure with preserved versus reduced ejection fraction","volume":"13","author":"Joseph J","year":"2022","unstructured":"Joseph J, Liu C, Hui Q, et al.. Genetic architecture of heart failure with preserved versus reduced ejection fraction. Nat Commun. 2022, 13:7753. 10.1038\/s41467-022-35323-0","journal-title":"Nat Commun"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-024-01589-2","article-title":"Obesity and metabolic syndrome in patients with heart failure with preserved ejection fraction: a cross-sectional analysis of the Veradigm Cardiology Registry","volume":"24","author":"Bae JP","year":"2024","unstructured":"Bae JP, Kallenbach L, Nelson DR, Lavelle K, Winer-Jones JP, Bonafede M, Murakami M. Obesity and metabolic syndrome in patients with heart failure with preserved ejection fraction: a cross-sectional analysis of the Veradigm Cardiology Registry. BMC Endocr Disord. 2024, 24:59. 10.1186\/s12902-024-01589-2","journal-title":"BMC Endocr Disord"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbad005","article-title":"Circulating metabolic signatures of heart failure in precision cardiology","volume":"6","author":"Xie H","year":"2023","unstructured":"Xie H, Zhang B, Xie M, Li T. Circulating metabolic signatures of heart failure in precision cardiology. Precis Clin Med. 2023, 6:pbad005. 10.1093\/pcmedi\/pbad005","journal-title":"Precis Clin Med"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2024.04.008","article-title":"Towards metabolomic-based precision approaches for classifying and treating\u00a0heart\u00a0failure","volume":"9","author":"Hahn VS","year":"2024","unstructured":"Hahn VS, Selvaraj S, Sharma K, Shah SH. Towards metabolomic-based precision approaches for classifying and treating\u00a0heart\u00a0failure. JACC Basic Transl Sci. 2024, 9:1144-58. 10.1016\/j.jacbts.2024.04.008","journal-title":"JACC Basic Transl Sci"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1159\/000534155","article-title":"Biomarker phenotypes in heart failure with preserved ejection fraction using hierarchical clustering-a pilot study","volume":"32","author":"Mitic V","year":"2023","unstructured":"Mitic V, Stojanovic D, Deljanin-Ilic M, Petrovic D, Ignjatovic A, Milenkovic J. Biomarker phenotypes in heart failure with preserved ejection fraction using hierarchical clustering-a pilot study. Med Princ Pract. 2023, 32:297-307. 10.1159\/000534155","journal-title":"Med Princ Pract"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24226-1","article-title":"Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events","volume":"12","author":"Regan JA","year":"2022","unstructured":"Regan JA, Truby LK, Tahir UA, et al.. Protein biomarkers of cardiac remodeling and inflammation associated with HFpEF and incident events. Sci Rep. 2022, 12:20072. 10.1038\/s41598-022-24226-1","journal-title":"Sci Rep"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13050746","article-title":"Personalized management for heart failure with preserved ejection fraction","volume":"13","author":"Lin CY","year":"2023","unstructured":"Lin CY, Sung HY, Chen YJ, Yeh HI, Hou CJ, Tsai CT, Hung CL. Personalized management for heart failure with preserved ejection fraction. J Pers Med. 2023, 13:746. 10.3390\/jpm13050746","journal-title":"J Pers Med"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2021.12.007","article-title":"Under-enrollment of obese heart failure with preserved ejection fraction patients in major HFpEF clinical trials","volume":"28","author":"Vaishnav J","year":"2022","unstructured":"Vaishnav J, Yanek LR, Hahn VS, Yang E, Trivedi R, Kass DA, Sharma K. Under-enrollment of obese heart failure with preserved ejection fraction patients in major HFpEF clinical trials. J Card Fail. 2022, 28:723-31. 10.1016\/j.cardfail.2021.12.007","journal-title":"J Card Fail"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028365","article-title":"Obese heart failure with preserved ejection fraction phenotype: from pariah to central player","volume":"136","author":"Kitzman DW","year":"2017","unstructured":"Kitzman DW, Lam CS. Obese heart failure with preserved ejection fraction phenotype: from pariah to central player. Circulation. 2017, 136:20-3. 10.1161\/CIRCULATIONAHA.117.028365","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/344029-obesity-related-phenotype-of-heart-failure-with-preserved-ejection-fraction-a-comprehensive-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T15:42:11Z","timestamp":1743435731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/344029-obesity-related-phenotype-of-heart-failure-with-preserved-ejection-fraction-a-comprehensive-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":96,"URL":"https:\/\/doi.org\/10.7759\/cureus.81512","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}